Division of Urologic Surgery

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Nephrectomy 67%
3. Prostate 48%
4. Kidney 44%
5. Prostatectomy 41%
6. Robotics 40%
7. Prostate-Specific Antigen 33%
8. Dutasteride 31%
9. Urinary Bladder 31%
10. Neoplasms 31%
11. Biopsy 26%
12. Urinary Bladder Neoplasms 25%
13. Cystectomy 24%
14. Renal Cell Carcinoma 23%
15. Pelvic Pain 23%
16. Lower Urinary Tract Symptoms 23%
17. Early Detection of Cancer 20%
18. Chronic Pain 17%
19. Prostatic Hyperplasia 17%
20. Interstitial Cystitis 16%
21. Therapeutics 15%
22. Watchful Waiting 13%
23. Survival 12%
24. Overactive Urinary Bladder 11%
25. Pain 11%
26. Surgeons 11%
27. Ovarian Neoplasms 11%
28. Carcinoma 11%
29. Urinary Incontinence 10%
30. Laparoscopy 10%
31. Swine 10%
32. Recurrence 10%
33. Lung Neoplasms 10%
34. Urinary Tract 9%
35. Finasteride 9%
36. Colorectal Neoplasms 9%
37. Operative Time 9%
38. Ureter 9%
39. Cryosurgery 8%
40. Nephroureterectomy 8%
41. Mortality 8%
42. Kidney Neoplasms 8%
43. Placebos 8%
44. Databases 7%
45. Percutaneous Nephrolithotomy 7%
46. Lymph Node Excision 7%
47. Ureteroscopy 7%
48. Urinary Diversion 7%
49. Confidence Intervals 7%
50. Serum 7%
51. Urinary Tract Infections 7%
52. Genome-Wide Association Study 7%
53. Warm Ischemia 7%
54. Urine 7%
55. Castration 7%
56. Wounds and Injuries 7%
57. Systematic Reviews 6%
58. Incidence 6%
59. Length of Stay 6%
60. Single Nucleotide Polymorphism 6%
61. Urologists 6%
62. Quality of Life 6%
63. Protein-Tyrosine Kinases 6%
64. Neoplasm Grading 6%
65. Odds Ratio 6%
66. Artificial Urinary Sphincter 6%
67. Guidelines 6%
68. Urology 6%
69. Nephrons 6%
70. Stress Urinary Incontinence 6%
71. Safety 5%
72. Morbidity 5%
73. Drug Therapy 5%
74. Androgen Receptors 5%
75. Comorbidity 5%
76. Cohort Studies 5%
77. Androgens 5%
78. Pediatrics 5%
79. Neoplasm Metastasis 5%
80. Digital Rectal Examination 5%
81. Stents 5%
82. Learning Curve 5%
83. Population 5%
84. Margins of Excision 5%
85. Multiparametric Magnetic Resonance Imaging 5%
86. Radiotherapy 5%
87. Equipment and Supplies 5%
88. Magnetic Resonance Imaging 5%
89. Logistic Models 5%